In Vitro Diagnostics Market Study Highlights How Industry Demand Is Evolving

The in vitro diagnostics market is on track for substantial growth over the coming years, driven by advances in technology and increasing demand for faster, more reliable testing. As healthcare continues to evolve towards personalized and decentralized approaches, the market is poised to transform significantly. Let's explore the current valuation outlook, key players, technological trends, and detailed market segments shaping this dynamic industry.

Expected Market Valuation and Growth Trajectory of the In Vitro Diagnostics Market
The in vitro diagnostics market is projected to expand rapidly, reaching a valuation of $241.14 billion by 2030. This impressive growth corresponds to a compound annual growth rate (CAGR) of 12.2% during the forecast period. Several factors are contributing to this expansion, including the widespread adoption of decentralized diagnostics, increasing investments in molecular testing technologies, and the growing presence of personalized medicine diagnostics. Additionally, there is rising demand for rapid and precise testing methods alongside the integration of AI-driven diagnostic tools. Prominent trends shaping the market include the increased use of point-of-care diagnostic devices, growing preference for molecular and immunoassay testing, wider implementation of automated laboratory systems, expansion of multiplex diagnostic platforms, and a stronger emphasis on rapid testing solutions.

Download a free sample of the in vitro diagnostics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13065&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Top Companies Driving the In Vitro Diagnostics Market Forward
The in vitro diagnostics field is dominated by several influential corporations that have established strong positions globally. These include Siemens Healthineers, F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Alere Inc., Arkray Inc., Becton dic*kinson and Company (BD), Bio-Rad Laboratories Inc., bioMérieux SA, Grifols SA, Hologic Inc., Werfen SA, Laboratory Corporation, Luminex Corporation, Ortho Clinical Diagnostics, PerkinElmer Inc., Qiagen NV, Quest Diagnostics Inc., QuidelOrtho Corporation, Sysmex Corporation, Illumina Inc., Menarini Silicon Biosystems SPA, SpeeDx Pty. Ltd., GENSPEED Biotech GmbH, Accelerate Diagnostics Inc., Merck KGaA, Caris Life Sciences Inc., Bio-Techne Corporation, Myriad Genetics Inc., Genomic Health Inc., Exact Sciences Corp., Natera Inc., Invitae Corp., and Veracyte Inc.

Recent Strategic Moves Enhancing Market Capabilities
In June 2025, bioMérieux, a leading in vitro diagnostics provider based in France, completed the acquisition of Day Zero Diagnostics for around $25 million. This acquisition is aimed at boosting bioMérieux's next-generation sequencing (NGS) capabilities and strengthening its portfolio in rapid diagnostics. The move is particularly focused on addressing antibiotic-resistant infections and improving management of severe infectious diseases. Day Zero Diagnostics, headquartered in the US, specializes in infectious disease diagnostics through genome sequencing and machine learning technologies that enable rapid identification of bacterial pathogens and their antibiotic resistance profiles directly from whole blood samples.

View the full in vitro diagnostics market report:
https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Technological Advancements Driving New Opportunities in In Vitro Diagnostics
Leading players in the market are increasingly adopting cutting-edge technologies such as UIMG image technology and 2D decoder chips to enhance test accuracy, efficiency, and workflow. UIMG image technology provides high-resolution imaging for better visualization and analysis of biological samples, contributing to improved diagnostic outcomes. For example, in November 2023, a technology company based in Newland, EMEA, Netherlands, launched a new in vitro diagnostics product line featuring five barcode scanners designed to be compact, rugged, and optimized for automated diagnostic processes. These scanners aim to speed up and improve the precision of diagnostics - a critical capability given the growing demand for efficient healthcare solutions.

Detailed Segment Breakdown of the In Vitro Diagnostics Market
This market is categorized into several key segments to better understand its structure and growth areas:

By Diagnostic Type:
- Point-of-Care Diagnostics Devices and Equipment
- Immunochemistry Diagnostic Devices and Equipment
- Clinical Chemistry Diagnostics Devices and Equipment
- Molecular Diagnostics Devices and Equipment
- Microbiology Diagnostic Devices and Equipment
- Hemostasis Diagnostic Devices and Equipment
- Hematology Diagnostic Devices and Equipment
- Immunohematology Diagnostic Devices and Equipment

By Type of Expenditure:
- Public
- Private

By End User:
- Hospitals and Clinics
- Diagnostic Laboratories
- Other End Users

Subsegment details include:
Point-of-Care Diagnostics Devices and Equipment cover blood glucose monitoring, pregnancy and fertility testing, infectious disease testing, cardiac markers testing, and coagulation testing. Immunochemistry devices include Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA), Western Blot, Immunofluorescence Assay, and Chemiluminescence Immunoassay (CLIA). Clinical Chemistry encompasses tests like blood glucose, cholesterol, liver and kidney function, and electrolyte testing. Molecular Diagnostics include PCR instruments, Next-Generation Sequencing (NGS) instruments, microarray devices, and Fluorescence In Situ Hybridization (FISH) technologies. Microbiology diagnostics cover microbial culture systems, automated identification, antimicrobial susceptibility testing, and blood culture systems. Hemostasis equipment features coagulation analyzers, thromboelastography systems, platelet function analyzers, and clotting factor analyzers. Hematology diagnostics include hematology analyzers, hemoglobin testing, complete blood count (CBC) devices, and blood cell counters. Immunohematology devices consist of blood typing, crossmatching, antibody screening, and blood bank analyzers.

This comprehensive segmentation offers a clear picture of the market's diverse offerings and the evolving healthcare needs they serve.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.